Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Author Correction: Morbidity of SARS-CoV-2 in the evolution to endemicity and in comparison with influenza.
Journal: Communications medicine
Published: January 08, 2025
A Randomized, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of VIR-2482 in Healthy Adults for Prevention of Influenza A Illness (PENINSULA).
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: April 03, 2024
A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness.
Journal: Antimicrobial agents and chemotherapy
Published: February 20, 2024
Morbidity of SARS-CoV-2 in the evolution to endemicity and in comparison with influenza.
Journal: Communications medicine
Published: December 12, 2023
Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial.
Journal: Infectious diseases and therapy
Published: October 23, 2023
Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial.
Journal: Open forum infectious diseases
Published: June 26, 2023
Population pharmacokinetics and exposure-response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID-19.
Journal: CPT: pharmacometrics & systems pharmacology
Published: November 23, 2022
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA.
Journal: Infectious diseases and therapy
Published: November 04, 2022
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Journal: JAMA
Published: March 14, 2022
Antibody therapy reverses biological signatures of COVID-19 progression.
Journal: Cell reports. Medicine
Published: February 09, 2022
Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy Adults.
Journal: Clinical drug investigation
Published: February 02, 2021
Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Published: October 25, 2019
Last Updated: 09/26/2026